US approves first nasal spray for anaphylaxis

The US Food and Drug Administration (FDA) has approved the first adrenaline (epinephrine) nasal spray, known as neffy, for the emergency treatment of allergic reactions, including those that are life threatening, in adults and children who weigh at least 30 kg.Neffy is a single dose nasal spray administered into one nostril, although as with adrenaline injection devices, a second dose can be given if there is no improvement in symptoms or symptoms worsen. Before neffy’s approval, adrenaline was available only as an injection.Kelly Stone, associate director of the division of pulmonology, allergy, and critical care in the FDA’s Center for Drug Evaluation and Research, said, “Anaphylaxis is life threatening and some people, particularly children, may delay or avoid treatment due to fear of injections. The availability of epinephrine nasal spray may reduce barriers to rapid treatment of anaphylaxis. As a result, neffy provides an important treatment option and addresses an…
Read Original Article: US approves first nasal spray for anaphylaxis »